23andMe

23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Friday, April 5, 2024
23andMe, Prevalence, Plasma, Genetics, NKG2D, Patient, SAN, Neoplasm, Data, Endothelium, Immunodeficiency, Cancer, Adenocarcinoma, PBMC, Biology, CD200, AACR, Therapy, Immunohistochemistry, NK, Carcinoma, The Cancer Genome Atlas, PD-1, Vaccine

Data also show soluble ULBP6 is a dominant immunosuppressor compared to other soluble NKG2D ligands due to its highest binding affinity to NKG2D among all NKG2D ligands.

Key Points: 
  • Data also show soluble ULBP6 is a dominant immunosuppressor compared to other soluble NKG2D ligands due to its highest binding affinity to NKG2D among all NKG2D ligands.
  • ULBP6 is a stress-induced ligand that is upregulated on the surface of cancer cells and binds to the activating immunoreceptor NKG2D found on NK and T cells.
  • The presentations will be available on the 23andMe Investor Relations and Therapeutics websites on April 8, 2024.
  • Title: 23ME-01473, a novel anti-ULBP6/2/5 monoclonal antibody, reinvigorates anti-tumor NK cell function through NKG2D and FcγRIIIa activation

23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

Retrieved on: 
Wednesday, March 20, 2024
23andMe, Genetics, Patient, SAN, Database, Research, Therapy, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-01473 (‘1473) in advanced solid tumors.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-01473 (‘1473) in advanced solid tumors.
  • The target for the new investigational antibody, ULBP6, was discovered through 23andMe’s proprietary research platform, the world's largest recontactable database of de-identified human genetic and phenotypic information.
  • This is the third drug target genetically validated by the 23andMe research platform to enter the clinic in under 4 years.
  • “We are excited to be underway in our study of ‘1473, and we are grateful to the patients participating in this trial.”

23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago

Retrieved on: 
Tuesday, March 19, 2024
23andMe, African Americans, Iron Age, Farmer, Silver, CE, Indigenous peoples, Genetics, Yellow, Harvard University, SAN, Continental Army, City, DNA, History, Metal, Indian Army Public Schools, African, BCE, Late, Bronze Age, Iron

"23andMe's Historical Matches is a technical breakthrough in our ability to accurately detect genetic connections between customers and historical individuals."

Key Points: 
  • "23andMe's Historical Matches is a technical breakthrough in our ability to accurately detect genetic connections between customers and historical individuals."
  • The new Historical Matches feature leverages the same science applied in a more consumer-friendly and approachable way to making these connections.
  • To create this new feature and connect members to Historical Matches, 23andMe identifies segments of DNA that individuals share with the genetic sequences of historical individuals.
  • The feature relies on publicly available data, scientific publications, and the 23andMe relative matching technology to link to these historical individuals.

Telehealth Pioneer Paul Johnson Joins DeepX Health Advisory Board

Retrieved on: 
Tuesday, April 2, 2024
Diagnosis, 23andMe, Skin cancer, LloydsPharmacy, Business, Health, Acquisition, University, Silicon, Walgreens Boots Alliance, Pharmaceutical industry

WASHINGTON, April 2, 2024 /PRNewswire-PRWeb/ -- DeepX Health is pleased to announce the appointment of Paul Johnson to its advisory board. Mr. Johnson brings a wealth of experience in the healthcare and technology sectors, with a proven track record of building and scaling innovative healthcare businesses.

Key Points: 
  • DeepX Health appoints healthcare industry veteran Paul Johnson to its advisory board to leverage his experience in scaling healthcare businesses.
  • WASHINGTON, April 2, 2024 /PRNewswire-PRWeb/ -- DeepX Health is pleased to announce the appointment of Paul Johnson to its advisory board.
  • Mr. Johnson was the founder and CEO of Lemonaid Health, a pioneering online healthcare company that he successfully led through an acquisition by 23andMe.
  • "As a new advisory board member, I'm excited to join DeepX Health, one of the pioneers in AI-driven cancer diagnostics," said Paul Johnson.

23andMe Launches New Genetic Reports on Common Forms of Cancer

Retrieved on: 
Wednesday, March 6, 2024
African Americans, SAN, Breast cancer, American Cancer Society, Cancer, Breast, 23andMe, Health, Genetics, Genomic Health, Database, PRS, Genetic, Patient, Black, Disease, Machine learning, Colorectal cancer, Premium, Research, Prostate cancer, Dietary supplement

The reports are based on statistical models known as polygenic risk scores (PRS), developed by 23andMe through its proprietary research database.

Key Points: 
  • The reports are based on statistical models known as polygenic risk scores (PRS), developed by 23andMe through its proprietary research database.
  • Availability of the breast cancer and prostate cancer PRS reports is based on self-reported birth sex.
  • The PRS models on which the new 23andMe reports are based were developed using the 23andMe database, and further validated using an external database.
  • To learn more about the new 23andMe PRS reports on cancer, and becoming a 23andMe+ Premium member, visit https://www.23andme.com/membership/ .

23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Tuesday, March 5, 2024
SAN, 23andMe, FDA, Cancer, AACR, Therapy, Genetics, NK, NKG2D, Cell death, Biology, IND, Vaccine

These presentations will be the first scientific communications the Company has prepared on ‘1473 since announcing its pursuit of this novel, genetically-validated target.

Key Points: 
  • These presentations will be the first scientific communications the Company has prepared on ‘1473 since announcing its pursuit of this novel, genetically-validated target.
  • Further, ‘1473 is Fc-effector enhanced, which provides an additional mechanism for NK cells to induce cell death of ULBP6-expressing cancer cells.
  • The presentations will be available on the 23andMe Investor Relations and Therapeutics websites on April 5, 2024.
  • Title: 23ME-01473, a novel anti-ULBP6/2/5 monoclonal antibody, reinvigorates anti-tumor NK cell function through NKG2D and FcγRIIIa activation

23andMe Reports Third Quarter Fiscal 2024 Financial Results

Retrieved on: 
Wednesday, February 7, 2024
GSK plc, PGS, Pharmacokinetics, SAN, Growth, Net, Inflammation, Table, Investigational New Drug, Research, SITC, Genetics, NK, Society, Consumer, Patient, IND, African Americans, FDA, Database, Immunotherapy, Therapy, Total, Premium, Webcast, Cancer, 23andMe, GSK, Workforce, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third quarter of fiscal year 2024 (FY24), which ended December 31, 2023.
  • “The Company had a very productive third quarter, with meaningful strategic progress across all three business lines,” said Anne Wojcicki, Co-Founder & CEO of 23andMe.
  • Full year Adjusted EBITDA deficit is adjusted to be in the range of $185 to $180 million for fiscal year 2024.
  • 23andMe will host a conference call at 4:30 p.m. Eastern Time today, February 7, 2024, to discuss the financial results for Q3 FY2024 and report on business progress.

23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay

Retrieved on: 
Wednesday, January 31, 2024
ARRAY, Pulitzer, Knowledge, Human, History, DNA, Origin, Academy Awards, Pulitzer Prize, Beauty, 23andMe

SUNNYVALE, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, announced a month-long initiative to amplify Ava DuVernay’s new film ORIGIN and the film’s groundbreaking Seat16 program.

Key Points: 
  • SUNNYVALE, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, announced a month-long initiative to amplify Ava DuVernay’s new film ORIGIN and the film’s groundbreaking Seat16 program.
  • For 23 days, 23andMe will donate 100 seats daily to support the program.
  • ARRAY, the multi-platform arts and social impact collective founded by Ava DuVernay, created the Seat16 initiative to ensure that 10,000 young people across the nation get to experience ORIGIN.
  • Through her foundation, 23andMe co-founder and CEO Anne Wojcicki helped fund the film along with several other non-profits.

23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

Retrieved on: 
Wednesday, January 31, 2024
Immune system, Trial of the century, Genetics, NK, Patient, FDA, Database, Food, FC, Cell death, Therapy, Cancer, 23andMe, NKG2D, Vaccine

23andMe plans to evaluate ‘1473 in participants with advanced solid tumors in a Phase 1 clinical study beginning in the first half of 2024.

Key Points: 
  • 23andMe plans to evaluate ‘1473 in participants with advanced solid tumors in a Phase 1 clinical study beginning in the first half of 2024.
  • ‘1473 targets ULBP6 to restore anti-tumor immunity through NK and T cells.
  • Further, ‘1473 is Fc-effector enhanced, which provides an additional mechanism for NK cells to induce cell death of ULBP6-expressing cancer cells.
  • “This program further validates the 23andMe database as a proven resource for identifying novel therapeutic targets,” said Jennifer Low, Head of Therapeutics Development, 23andMe.

Regula Urges Awareness as Identity Theft Soars to a Record 3205 Data Compromises

Retrieved on: 
Tuesday, January 30, 2024
Transfer, IDV, Ashkenazi Jews, Roger Hawkins (drummer), Record, Identity theft, American Express, Facial recognition, Face, Weapon, NFC, Sheep, Identity, AI, Iris, 23andMe, Theft, Airport, Regula, Apple, Goat, RFID, ID, Annual report, Progress Software, MyGov, Changi Airport, Cryptocurrency

RESTON, Va., Jan. 30, 2024 /PRNewswire/ -- In a landscape saturated with staggering statistics, the need for innovative solutions to safeguard against the usage of stolen identities becomes more pronounced. The gravity of identity-related crimes is illustrated by the Identity Theft Resource Center's annual report, disclosing a record 3205 data compromises in 2023, marking a seismic 78% increase from the prior year. These breaches facilitated hackers in gaining unauthorized access to the personal information of millions of consumers.

Key Points: 
  • Amidst an alarming surge in identity-related crimes, Regula, a global developer of forensic devices and identity verification solutions, calls for heightened vigilance during Identity Theft Awareness Week.
  • The gravity of identity-related crimes is illustrated by the Identity Theft Resource Center's annual report , disclosing a record 3205 data compromises in 2023, marking a seismic 78% increase from the prior year.
  • Shields Healthcare Group, a Massachusetts-based medical services provider, saw the theft of sensitive patient information and confidential data in a breach that affected approximately 2.3 million people.
  • The breach exposed large volumes of often-sensitive data, including pension information, social security numbers, medical records, and billing data.